Experimental PSP drug NIO752 enters early human safety testing
NCT ID NCT04539041
First seen Jan 08, 2026 · Last updated May 13, 2026 · Updated 23 times
Summary
This early-stage trial tested the safety of a new drug called NIO752 in 59 people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. Participants received multiple doses of the drug or a placebo injected into the spinal fluid. The main goal was to check for side effects and how the drug moves through the body, not to measure if it improves symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY (PSP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Novartis Investigative Site
Montreal, Quebec, H2X 1R9, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3A 2B4, Canada
-
Novartis Investigative Site
Bonn, North Rhine-Westphalia, 53127, Germany
-
Novartis Investigative Site
Düsseldorf, 40225, Germany
-
Novartis Investigative Site
Hanover, 30625, Germany
-
Novartis Investigative Site
München, 81377, Germany
-
Novartis Investigative Site
Tübingen, 72076, Germany
-
Novartis Investigative Site
Ulm, 89081, Germany
-
Novartis Investigative Site
Southampton, SO16 6YD, United Kingdom
-
University of California San Diego
La Jolla, California, 92037, United States
-
Vanderbilt University Medical CenterX
Nashville, Tennessee, 37221, United States
Conditions
Explore the condition pages connected to this study.